Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icovamenib in Type 2 Diabetes
NCT07502495Phase 2Active, not recruiting
- Sponsor
- Biomea Fusion
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of icovamenib in type 2 diabetes mellitus (T2DM), sponsored by Biomea Fusion. Started Mar 2026; status: active, not recruiting.
02
Drugs
icovamenib
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07502495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07502495.